600
Participants
Start Date
January 28, 2025
Primary Completion Date
November 30, 2026
Study Completion Date
December 31, 2026
KBP-336
KBP-336 is a long acting Dual Amylin and Calcitonin Receptor agonist designed for weekly administration through subcutaneous injection.
Placebo
Placebo to match KBP-336
NOT_YET_RECRUITING
Pratia Brno, s.r.o, Brno
NOT_YET_RECRUITING
L.K.N. Artrocentrum, Hlučín
NOT_YET_RECRUITING
Medical Plus, s.r.o, Hradiště
NOT_YET_RECRUITING
Pratia Pardubice a.s., Pardubice
NOT_YET_RECRUITING
Affidea Praha s.r.o, Prague
NOT_YET_RECRUITING
Pratia Prague, s.r.o, Prague
RECRUITING
Sanos Clinic Nordjylland, Gandrup
RECRUITING
Sanos Clinic Herlev, Herlev
RECRUITING
Sanos Clinic Syddanmark, Vejle
NOT_YET_RECRUITING
Hong Kong Center for Clinical Research, Hong Kong
NOT_YET_RECRUITING
"IMSP Sptalul Clinic Municipal Sfanta Treime", Chisinau
NOT_YET_RECRUITING
PMSI Cardiology Institute/RTL SM SRL, Chisinau
NOT_YET_RECRUITING
Timofei Mosneaga Republican Clinical Hospital, Chisinau
NOT_YET_RECRUITING
NZOZ Bif-Med. s.c., Bytom
NOT_YET_RECRUITING
Medyczne Centrum Hetmańska, Poznan
NOT_YET_RECRUITING
DC-MED SP z o.o., Swidnica
NOT_YET_RECRUITING
NZOZ Lecznica MAK-MED s.c., Warsaw
NOT_YET_RECRUITING
Migre Polskie Centrum Leczenia Migreny, Wroclaw
NOT_YET_RECRUITING
Policlinica CCBR, Bucharest
NOT_YET_RECRUITING
Quantum Medical Bucharest, Bucharest
Lead Sponsor
KeyBioscience AG
INDUSTRY